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Vaccines are critical in the fight against infectious diseases, and immune-stimulating 
adjuvants are essential for enhancing vaccine efficacy. However, the precise mecha-
nisms of action of most adjuvants are unknown. There is an urgent need for customized 
and adjuvant formulated vaccines against immune evading pathogens that remain a risk 
today. Understanding the specific role of various cell types in adjuvant-induced protective 
immune responses is vital for an effective vaccine design. We have investigated the role 
of cell-specific MyD88 signaling in vaccine adjuvant activity in vivo, using Neisserial porin 
B (PorB), a TLR2 ligand-based adjuvant, compared with an endosomal TLR9 ligand 
(CpG) and toll-like receptor (TLR)-independent (alum, MF59) adjuvants. We found that 
intact MyD88 signaling is essential, separately, in all three antigen-presenting cell types 
[B cells, macrophages, and dendritic cells (DCs)] for optimal TLR ligand-based adjuvant 
activity. The role of MyD88 signaling in B cell and DC in vaccine adjuvant has been pre-
viously investigated. In this study, we now demonstrate that the immune response was 
also reduced in mice with macrophage-specific MyD88 deletion (Mac-MyD88−/−). We 
demonstrate that TLR-dependent adjuvants are potent inducers of germinal center (GC) 
responses, but GCs are nearly absent in Mac-MyD88−/− mice following immunization 
with TLR-dependent adjuvants PorB or CpG, but not with TLR-independent adjuvants 
MF59 or alum. Our findings reveal a unique and here-to-for unrecognized importance of 
intact MyD88 signaling in macrophages, to allow for a robust vaccine-induced immune 
responses when TLR ligand-based adjuvants are used.
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inTrODUcTiOn
Immune adjuvants are necessary in most, if not all, vaccines, to enhance efficacy by increasing the 
immunogenicity of poorly immunogenic antigens. Adjuvants can be either exogenously added or 
are inherent in the vaccine preparations, e.g., live attenuated or killed whole organism vaccines. 
The majority of adjuvants originate from microbial components, referred to as pathogen-associated 
molecular patterns (PAMPs). Our immune system has evolved to respond to these PAMPs and 
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stimulate innate immune responses through germline-encoded 
pattern recognition receptors. Toll-like receptors (TLRs) are 
some of the best-studied PPRs used by the immune system to 
respond to PAMPs. Vaccines containing TLR ligand-based adju-
vants activate and trigger innate immune responses to enhance a 
potential protective immune response induced by vaccines (1).
Adjuvants shape the character and intensity of responses 
triggered in vivo. Moreover, the mechanism of action for most 
adjuvants is not very well understood. Therefore, in this study, a 
variety of well-characterized TLR-dependent [porin B (PorB)—
TLR2, CpG—TLR9] and TLR-independent adjuvants (alum, 
MF59) were examined. PorB is the major outer membrane 
protein from Neisseria meningitidis (2). This protein has been 
investigated as a potential anti-Neisserial vaccine candidate 
(3–5), through this work it was found that this protein had potent 
immune stimulatory abilities beyond its own potential use as a 
vaccine. PorB stimulates antigen-presenting cells (APCs) through 
direct interaction with TLR2/TLR1 heterodimers and requires the 
adaptor protein MyD88 for this stimulation to occur (6–9). In this 
study, we compared PorB with an endosomal TLR9-dependent 
adjuvant; CpG DNA (CpG). CpG is a TLR9/MyD88-dependent 
adjuvant composed of unmethylated bacterial DNA motifs (10). 
In addition, PorB was also compared to alum salt and MF59, two 
TLR-independent adjuvants. Alum is the first adjuvant approved 
by the FDA, has been in use for over 80 years in millions of vac-
cine doses, and induces mainly Th2 type immune responses and 
its effect is MyD88 and TRIF independent (11). MF59, consists 
of an oil-in-water squalene solution, has been a licensed adju-
vant in the formulation of the influenza vaccines since 1994 in 
Europe (Novartis Vaccines). The adjuvanticity of MF59 is still 
being investigated and appears to be MyD88 dependent but TLR 
independent (12).
Toll-like receptors are commonly expressed in various cell 
types, especially APCs, including dendritic cells (DCs), B cells, 
and macrophages (13, 14). TLR ligand-based adjuvants are used 
in vaccines to stimulate these immune cells, to induce, and to 
boost protective immune responses, linking the innate and adap-
tive immunity (1). Investigators have shown that incorporation of 
glucopyranosyl lipid adjuvant (binding to TLR4) in an oil-/water-
emulsified malaria vaccine or in an investigative tuberculosis 
vaccine can greatly increase diversity of the antibody repertoire 
and enhance protection in animal models (15, 16). The successful 
yellow fever vaccine has been shown to activate multiple subsets 
of DCs by signaling through a specific set of TLRs (TLR2, 7, 8, 
and 9) (17). Absence of one of these TLRs altered and diminished 
the type of responses by the vaccine in vitro in DCs (17).
Previous studies have established that TLR recognition and 
signaling via the MyD88 adaptor protein are crucial for immune 
responses triggered by TLR ligand-based vaccine formulations 
(18). MyD88 signaling in B cells in vivo is critical for induction 
of antibody-secreting cells upon vaccination (19). It is also 
important for induction of antiretroviral germinal center (GC) 
response (20) and required for induction of functional CD4 T 
cells producing IFN-γ for the control of IgG2c subclass produc-
tion (21). Generation of T cell-dependent (TD) antigen-specific 
antibody responses requires TLR and MyD88 signaling in naïve 
human B cells and that TLR stimulation of DCs alone is not 
sufficient to induce TD B-cell responses (22, 23). GC formation 
is crucial for the production of antibody-secreting cells including 
memory B cells, which produce class switched isotypes and high 
affinity antigen-specific antibodies, and is essential for a rapid 
recall response to antigens (24). Intact TLR-MyD88 signaling in 
B cells and DCs has previously been shown to be important for 
induction of robust GCs and antibody production upon stimula-
tion with TLR ligand-based adjuvants (25). Intrinsic DC-MyD88 
signaling in vivo was essential to trigger Th2/Th1 cells (26), the 
induction of a robust humoral response with CpG as a TLR9 
ligand (27) and activation of adaptive immune responses (28). 
However, the contribution of macrophage intrinsic MyD88 
signaling in TLR ligand-based vaccine adjuvant responses has 
not been investigated.
The impact of in  vivo MyD88 signaling in specific immune 
cells, e.g., B cells, DCs, or macrophages, on TLR ligand-based 
immunomodulation, and subsequent vaccine efficacy was exam-
ined in this study. We used the loxP/cre recombinase system 
to conditionally knock out MyD88 in individual APC types 
in vivo. Immunizations of these mice revealed the importance of 
functional cell-specific MyD88 signaling in the adjuvanticity of 
TLR-dependent and -independent adjuvants. Our findings con-
firm the importance of intact in vivo MyD88 signaling in B cells 
and DCs and reveal a here-to-for unrecognized importance in 
macrophages, demonstrating its contribution to a robust vaccine-
induced immune response, including GC formation, when TLR 
ligands are used as adjuvants.
aniMals anD MeThODs
animals
All mice including wild-type (WT) C57BL/6J were purchased 
from Jackson Laboratories. MyD88flox/flox (MyD88tm1Defr, stock 
# 008888) (28) mice were bred with CD19 Cre (Cd19tm(cre)
Cgn, stock # 006785) (29), CD11c Cre [Tg(Itgax-cre)1-1Reiz, 
stock # 008068] (30) or Lysm Cre (Lyz2tm1(cre)Ifo, stock # 
004781) (31) mice then crossed again with MyD88flox/flox to 
generate MyD88flox/flox homozygous and heterozygous Cre mice. 
MyD88flox/flox CD19Cre mice have a MyD88 deletion in CD19+ 
CD3− B cells (B-Cell-MyD88−/−). MyD88flox/flox CD11cCre mice 
have MyD88 deleted in CD11c+CD11b− DCs (DC-MyD88−/− 
mice). MyD88flox/flox LysmCre mice have a MyD88 deletion in 
CD11b+F4/80+ macrophages (Mac-MyD88−/− mice). All mice 
were maintained in the Association for Assessment and 
Accreditation of Laboratory Animal Care International accred-
ited facility at Boston University School of Medicine Laboratory 
Animal Science Center. All animal experiments were con-
ducted under the approved Institutional Animal Care and Use 
Committee (IACUC) protocol for Dr. Wetzler’s Laboratory at 
Boston University. Mice were genotyped by PCR using primer 
sequences recommended by Jackson Laboratories.
immunizations
Wild-type, B-cell-MyD88−/−, DC-MyD88−/−, and Mac-MyD88−/− 
mice between the ages of 6 and 12 weeks were immunized subcu-
taneously three times at 2-week intervals. Mice were immunized 
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with 10 μg of N. meningitidis PorB, or CpG (ODN1826, Invivogen) 
admixed with 10  μg of ovalbumin (OVA). Alum vaccinations 
contained 200 μg of aluminum hydroxide, alum (Sigma) mixed 
with 10 μg of OVA. MF59-based vaccines were prepared by mix-
ing 50 μl of MF59 (gift from Anja Seubert, Novartis Vaccines and 
Diagnostics) with 50 μl PBS containing 10 μg of OVA. Mice were 
immunized with either PBS or 10 μg OVA protein as controls. 
There were at least four mice per group and single experiments 
were repeated to obtain a total of eight mice per group. PorB was 
purified from N. meningitidis strain H44/76 Δ-1/4 (32) using 
protein extraction and column chromatography as previously 
described (33). Activity of PorB and endotoxin content were 
examined by stimulation of WT, MyD88−/−, TLR2−/−, and TLR4−/− 
BMDM, silver staining, and LAL assay (Pierce Endotoxin Kit 
from Life Technologies), no endotoxin was found in any prepara-
tion. The amount of adjuvants and antigen utilized were based 
on previously published studies and falls within the best range of 
their efficacy (6, 34–36). Sera were collected via tail bleed prior to 
each immunization and 2 weeks after the last immunization. For 
serum cytokine measurements, preimmune sera as well as sera 
from 4 h post immunization were collected. This time point was 
selected based on our examinations of different time points and 
previously published work (37).
Measurement of antigen-specific 
antibodies
Sera were assayed for OVA-specific immunoglobulins by enzyme-
linked immunosorbent assay as previously described (38, 39). 
Briefly, wells were coated with OVA (5 μg/mL) in carbonate buffer 
and incubated overnight at 4°C. Sera were sequentially diluted 
starting at 1:50 and added to the previously coated wells, and 
incubated overnight at 4°C. Alkaline phosphatase-conjugated 
anti-mouse total IgG or IgM (Sigma Aldrich, St. Louis, MO, USA) 
were added and the plates developed with one-step p-nitrophenyl 
phosphate (Pierce, Rockford, IL, USA) and the optical density at 
405 nm was measured on a SpectraMax190 Microplate Reader 
(Molecular Devices, Sunnyvale, CA, USA). Colorimetric values 
were converted to nanograms/milliliter, according to standard 
curves generated by known amounts of IgG as previously 
described (32) or known amounts of IgM using GraphPad Prism.
sectioning for Fluorescent Microscopy
Spleens were obtained 7 days after the second immunization of 
the mice and were embedded in optimal cutting temperature 
medium (Richard Allan Scientific, Kalamazoo, MI, USA) in 
molds (ThermoFisher) and flash frozen in an isopropanol dry ice 
bath and stored at −80°C. Sectioning was performed on a cry-
ostat (Microm HM 550, Microm International GmbH, Walldorf, 
Germany). Embedded spleens were removed from molds, placed 
on mounts, and allowed to equilibrate to the −20°C internal 
temperature of the cryostat for about 15 min. For initial trimming 
20 μm slices were made until the tissue was visible at the surface of 
the block. Sections of 8 μm thickness were obtained and placed on 
lysine treated slides (Colorfrost Plus, ThermoFisher). Six sections 
were cut per mouse and a total of 18 sections for the three mice 
per immunization group. About 24 μm or more of tissue were cut 
between the collected sections and special attention was given to 
the location of the GC upon imaging to prevent quantitation of 
the same GCs.
confocal Microscopy
Sections were air dried for 15  min at room temperature, then 
fixed in acetone at −20°C for 10 min and afterward air dried for 
10 min. Sections were rehydrated in tris-buffered saline solution 
(TBS) with 0.05% Tween-20 (TBS-T) then blocked for 20  min 
at room temperature with TBS-T with 5% BSA. Sections were 
rinsed with TBS-T and then stained with antibodies for 1 h fol-
lowed by two rinses with TBS-T and incubated in a TBS-T bath 
for 5 min on an orbital shaker. The following antibodies were used 
at 1 to 200 dilution: FITC Rat anti-Mouse B and T cell Activation 
Antigen Clone: GL7 (Beckton Dickinson Biosciences, San Jose, 
CA, USA), PE anti-Mouse IgD Clone: 11-26c.2a (BioLegend, San 
Diego, CA, USA) and Alexa Fluor 647 anti-Mouse TCR-β Clone: 
H57-597 (BioLegend, San Diego, CA, USA). Stained sections 
were mounted in fluoroshield mounting medium with DAPI 
(Abcam, Cambridge, MA, USA), covered with a cover glass, and 
dried overnight. A Leica TCS Sp5 DMI6000 confocal microscope 
(Leica AG, Wetzlar, Germany) was used to examine the sections 
using the Leica Application Suite Advanced Fluorescence soft-
ware. Four separate lasers were used to excite the four different 
fluorochromes and the appropriate gating was applied to prevent 
emission spectral overlap during capture. The 10× objective (HC 
PL FLUOTAR 10.0× 0.3 Dry) with a numerical aperture of 0.3 
was used to capture the images with four lines average at 200 Hz 
with a resolution of 1,024 × 1,024 and at 16 bit. The images were 
analyzed and area measured using Image processing analysis in 
Java (ImageJ, NIH). Areas less than 400 μm2 were excluded, as 
they could not be measured accurately using the freehand selec-
tion feature in the software.
Flow cytometry
Germinal center cells were examined using a BD LSRII Flow 
Cytometer (Beckton Dickinson Biosciences, San Jose, CA, USA) 
in the Boston University Flow Core. Spleens from mice (N = 3) 
were harvested 7 days after the second immunization and single 
cells suspension were prepared. Red Blood Cells were lysed with 
ammonium-chloride-potassium lysis buffer prepared in house 
(ACK Lysis Buffer). Cells were washed with cold FACS buffer 
(0.5% FBS +  2  mM EDTA in PBS) then stained for 30  min at 
4°C with fluorescently labeled antibodies in 40 μl of FACS buffer 
in 96-well plate then washed and transferred in FACS cluster 
tube for analysis. The following antibodies were used: FITC Rat 
anti-Mouse B and T cell Activation Antigen Clone: GL7, APC Rat 
anti-Mouse CD4 Clone RM4-5, Biotin Rat anti-Mouse CD45R/
B220 Clone: RA3-6B2 (Beckton Dickinson Biosciences, San Jose, 
CA, USA), and PE/Cy7 anti-Mouse CD19 Clone: 6D5 and PE 
Strepavidin (BioLegend, San Diego, CA, USA). Forward and side 
scatter gates were used to identify live cells (gating strategies were 
similar to Figures S1A–D in Supplementary Material) and cells 
that were CD4−, B220+, CD19+, and GL7+ were gated as GC B cells. 
All gates were based on PBS immunized mice as negative control. 
For lymphoid organs composition: single-cell suspensions from 
spleens and inguinal, axillary and brachial lymph nodes from 
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WT, B-Cell-MyD88−/−, DC-MyD88−/−, and Mac-MyD88−/− mice 
were prepared as described above. Cells were stained with 
fluorescently labeled antibodies and the number of CD8+ T-cells, 
CD11b+F4/80+ Macrophages, CD19+ B cells, CD11c int B220+ 
Ly6C+ CD19− pDCs, CD11c+B220− DCs, CD11b+Ly6G+ PMNs, 
NK1.1+CD4− T-cells, and CD4+ T-cells were measured by flow 
cytomteric analysis. Two mice per genotype were examined. 
Differences between the number of cells in WT and the different 
MyD88 Floxed mice were calculated using one-way ANOVA with 
Bonferroni test. Analysis was performed using FlowJo (Tree Star, 
Ashland, OR, USA).
Measurements of cytokines
Cytokine levels were measured from sera obtained 4 h post each 
immunization and compared to preimmune sera. Individual 
mouse sera (N = 4 mice per immunization group) screened on 
a MAGPIX XMAP instrument (Luminex, Austin, TX, USA) in 
duplicates using Mouse 20-plex cytokines kits (Life Technologies). 
Individual standard curves were generated for each cytokines 
and analyzed using the Luminex Xponent software. This experi-
ment was performed twice. Unknown sample concentration was 
extrapolated from standard curves for single analytes. All values 
outside of the standard curve limit were rejected.
statistical analysis
Statistics were calculated using with GraphPad Prism 6.0. 
Differences in OVA-IgG concentration between WT and the 
different MyD88 Floxed mice were calculated using one-way 
ANOVA with Tukey’s test. Differences in percentage of GC 
cells and area of GCs were calculated using the non-parametric 
Mann–Whitney U test. In all experiments, significance levels 
were defined as ns = P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001.
resUlTs
The requirement of In Vivo MyD88 
signaling in Macrophages, B cells, and 
Dcs, individually, for Tlr ligand-Based 
adjuvant Function
We have previously demonstrated that PorB lacks adjuvant 
activity in MyD88 KO mice (9). In this study, we examined 
the effect of deficient MyD88 signaling, separately, in each 
APC type, in regard to the adjuvant activity of PorB and CpG 
as TLR2 and TLR9 ligand-based adjuvants, respectively. We 
used MyD88 conditional KO mice, with APC-specific MyD88 
deletion in B cells, DCs, or macrophages. MyD88flx/flxCD19Cre, 
MyD88flx/flxCD11cCre, or MyD88flx/flxLysmCre mice (termed 
B-cell-MyD88−/−, DC-MyD88−/−, and Mac-MyD88−/− mice) were 
generated by breeding MyD88flx/flx mice with mice expressing 
Cre recombinase under cell-specific promoters. Previous studies 
have shown efficient deletion of MyD88 in DCs and B cells from 
the DC-MyD88−/− mice and B-cell-MyD88−/− mice, respectively 
(28), and macrophages from the Mac-MyD88−/− mice (40) 
utilizing this method. CD3−CD11c+CD11b− DCs, CD3−CD19+ 
(B cells), and CD11b+F4/80+ (macrophages) were sorted from 
WT, DC-MyD88−/−, B-cell-MyD88−/−, and Mac-MyD88−/− mice 
as shown in Figure S1 in Supplementary Material. MyD88 was 
efficiently deleted in the different mouse strains as measured by 
quantitative real-time PCR (Figure S2 in Supplementary Material) 
performed on genomic DNA isolated from sorted cells (Figure S1 
in Supplementary Material). Deletion of MyD88 was confined to a 
specific cell type while the other APC types expressed normal lev-
els of MyD88 (Figure S2 in Supplementary Material). Percentages 
and numbers of CD8+ T-cells, CD11b+F4/80+ Macrophages, 
CD19+ B cells, CD11c int B220+ Ly6C+ CD19− plasmacytoid DCs, 
CD11c+B220− DCs, CD11b+Ly6G+ PMNs, NK1.1+CD4− T-cells, 
and CD4+ T-cells from spleen and six different lymph nodes in 
these three transgenic mice were also examined. There were no 
significant differences in the major cell types as compared to 
WT mice suggesting that deletion of MyD88 in the specific cell 
types did not affect these cell populations in the lymphoid organs 
(Figures S3 and S4 in Supplementary Material).
Wild-type, B-cell-MyD88−/−, DC-MyD88−/−, and Mac-
MyD88−/− mice were immunized with OVA antigen alone or 
admixed with TLR-dependent or -independent adjuvants. The 
vaccine-induced antibody responses were measured 2  weeks 
after each immunization (Figure 1). OVA-specific IgM was only 
detected in mice immunized with OVA alone and only 14 days 
after the second immunization, for all examined immunization 
groups and time points (data not shown). One vaccination 
was not sufficient to trigger an OVA-specific IgG response in 
either TLR-dependent or -independent adjuvanted vaccines 
(Figure  1). Two weeks after the second vaccination WT mice 
had a low but detectable antigen-specific response to OVA when 
the TLR-dependent and -independent adjuvants were utilized, 
but these differences were not significantly different from the 
MyD88 conditional KO mice when PorB, MF59, or alum were 
used as adjuvants (Figure 1). Notably, OVA/CpG immunized WT 
mice had significantly higher OVA-specific IgG after the second 
immunization when compared to the various MyD88 conditional 
KO mice (Figure 1).
Wild-type mice mounted a robust anti-OVA antibody response 
after three immunizations using any of the adjuvant formula-
tions, while immunizations of the conditional MyD88 KO mice 
revealed that intact signaling through MyD88 was required in B 
cells, macrophages, or DCs for optimal adjuvant activity of the 
TLR2-dependent adjuvant PorB (Figure 1A). Similar results were 
observed when CpG, an endosomal TLR9 ligand, was used as an 
adjuvant. This indicates that intact MyD88 signaling is crucial for 
either TLR2 or TLR9 ligand-based adjuvants, which rely on the 
MyD88 adaptor protein to induce resilient antibody responses 
(Figure  1A). TLR-independent adjuvants in contrast, e.g., 
MF59 or alum, were able to trigger a vigorous humoral response 
against OVA in mice lacking MyD88 in any of the three APC 
types (Figure 1B). This suggests that the decrease in the humoral 
response when PorB or CpG were used as adjuvants is not due 
to an intrinsic defect in these mice, but, rather, to the specific 
absence of MyD88 signaling in all these APC types. These results 
demonstrate the importance of MyD88 signaling in all three APC 
types when TLR ligand-based adjuvants are used. In regard to 
macrophages, this is the first time to our knowledge that MyD88 
signaling was shown to be as important in this process.
FigUre 1 | intact in vivo MyD88 signaling in B cells, dendritic cells (Dcs), or macrophages is required for robust vaccine-induced humoral 
responses by toll-like receptor (Tlr)-based adjuvants. Total ovalbumin (OVA)-IgG concentrations were measured by enzyme-linked immunosorbent assay 
(ELISA) following immunization with (a) PBS, OVA alone or mixed with TLR-dependent adjuvants PorB, CpG or (B) with TLR-independent adjuvant MF59 or alum. 
Wild-type, Mac-MyD88−/−, DC-MyD88−/−, and B-cell-MyD88−/− mice, respectively, were immunized three times at 2-week interval. The results shown are from 
samples collected 2 weeks after each immunization and representative of two experiments with a total of four to eight mice per immunization. Statistics were 
calculated based on a non-parametrical one-way ANOVA with Tukey’s test (ns, not significant P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). 
Symbol (–) indicates that IgG levels were below detectable level.
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In Vivo cytokine responses require intact 
MyD88 signaling in B cells, Dcs, and 
Macrophages
Adjuvanted subunit vaccines almost always require repeated 
booster injections to induce sufficient protective IgG levels. The 
cytokine production during the initial induction of vaccine-
associated immune responses is important for the quality, robust-
ness, and longevity of the response. Therefore, we measured 
IL-1β, IL-6, IP-10, and the Th2/Th1 cytokines from sera collected 
4  h after each immunization (Figures  2 and 3). The selected 
cytokines were chosen because their essential roles in vaccine-
induced humoral and cellular immune responses (41–46). WT, 
DC-MyD88−/−, B-cell-MyD88−/−, and Mac-MyD88−/− mice were 
immunized with OVA admixed with TLR-dependent adjuvants 
PorB, CpG, or the TLR-independent adjuvant alum. Serum 
cytokine levels were undetectable or very low 4 h after the first 
immunization for most of the Th2/Th1 cytokines (data not 
shown). However, 4 h after the second immunization cytokines 
levels were increased in WT mice immunized with adjuvanted 
vaccines. Moreover, OVA/PorB immunized WT mice developed 
high levels of IL-1β, IL-6, and IP-10 (Figures 2A–C), while OVA/
PorB immunized Mac-MyD88−/− mice had similar levels of IL-6 
but diminished levels of IL-1β and IP-10 when compared to 
the WT mice (Figures 2A–C). In addition, deletion of MyD88 
in macrophages resulted in a more profound decrease in IL-1β, 
and IP-10 cytokines when TLR ligand-based adjuvants were used 
compared to TLR-independent adjuvants (Figures  2A–C). For 
example, IL-1β and IP-10 levels in mice immunized with OVA/
alum were not decreased in the Mac-MyD88−/− mice as compared 
to WT mice.
Interestingly, in contrast to the Mac-MyD88−/− mice, IL-6 
levels were increased in the DC-MyD88−/− mice compared to WT 
mice when immunized with either OVA/PorB or OVA/alum, sug-
gesting that the DCs may have some control over IL-6 induction 
that is MyD88 dependent. IP-10 and IL-6 levels were decreased in 
OVA/PorB immunized B-cell-MyD88−/− mice when compared to 
WT mice. In contrast to Mac-MyD88−/− or DC-MyD88−/− mice, 
IL-1β levels from B-cell-MyD88−/− mice remained comparable to 
WT mice.
Th1 and Th2 type cytokines in sera of vaccinated mice were 
measured four hours after each immunization. Following the 
first immunization there were very low or undetectable levels of 
Th2/Th1 type cytokines. However, four hours after the second 
immunization, formulations containing PorB induced high levels 
of IL-4, IL-5, and IL-13 (Th2 type cytokines, Figures 3A–C) as 
well as IFN-γ and IL-12 (Th1 type cytokines, Figures 3D,E) in 
WT mice. Selective deletion of MyD88 in macrophages resulted 
in a significant decrease in most of these cytokines except for 
IL-4 and IFN-γ, which remained unchanged (Figures 3A,D). As 
expected, TLR-dependent adjuvant CpG induced mainly a Th1 
type response as determined by cytokine responses (Figure  3) 
(10). Lack of MyD88 signaling in macrophages in vivo resulted 
in a significant decrease in IL-12, but not IFN-γ, when CpG was 
used as an adjuvant (Figures 3D,E), similar to the results observed 
with PorB. The TLR-independent adjuvant alum mainly induced 
Th2 type cytokines (as expected) in WT mice (47), and deletion 
of MyD88 in macrophages, in  vivo, resulted in non-significant 
decreases in the levels of the Th2 type cytokines except for IL-5, 
which was significantly decreased (Figures 3A–C). Interestingly, 
IL-4 levels were also decreased when alum was used as a vaccine 
adjuvant in Mac-MyD88−/− mice. This is in contrast to the TLR2 
FigUre 2 | effect of MyD88 signaling on cytokine induction upon vaccination. In vivo MyD88 signaling is important for the induction of (a) IL-1β, (B) IL-6, 
and (c) IP-10 cytokines. Serum cytokine levels were determined in vaccinated wild-type (WT), Mac-MyD88−/−, B-cell-MyD88−/−, and DC-MyD88−/− mice immunized 
two times at 2 weeks interval and serum collected 4 h after of the second immunization with PBS, ovalbumin (OVA), OVA + PorB, OVA + CpG, or OVA + alum 
measured by Luminex magnetic bead-based multiplex assay. The results shown are representative of one experiment (n = 4 mice); serum was analyzed individually 
in duplicates. This experiment was repeated twice. Symbol (–) indicates that cytokine levels were below detectable level. One-way ANOVA with Tukey’s test were 
used to calculate statistical differences between experimental groups and treatments (ns, not significant P > 0.05, *P < 0.05, **P < 0.01). All comparisons were 
made to WT mice.
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ligand-based adjuvant, PorB. Th2/Th1 type cytokine responses 
were differentially affected with the lack of MyD88 signaling in 
B cells or DCs in vivo. For example, DC-MyD88−/− mice immu-
nized with vaccine containing TLR2-dependent adjuvant PorB 
had a high level of systemic Th2 type cytokines, unlike what was 
observed with Mac-MyD88−/− mice. A different Th1 type cytokine 
profile was also observed in DC-MyD88−/− and B-cell-MyD88−/− 
mice upon immunization with TLR ligand-based adjuvants. The 
heterogeneity in the different adjuvant responses is likely due 
to the varied mechanism by which these adjuvants induce their 
responses.
intact In Vivo MyD88 signaling in 
Macrophages is required for gc 
Formation induced by Tlr ligand-Based 
adjuvants
The anti-OVA immune response induced by OVA/PorB or OVA/
CpG in Mac-MyD88−/− mice was much less as compared to WT 
mice (Figure 1A). The most effective humoral immune responses 
induced by vaccination rely on a class switch recombination, 
antibody somatic hypermutation, and affinity maturation, which 
all occur in GCs. A unique subset of macrophages resides in 
and around the lymphoid follicles where GCs form, MARCO1+ 
marginal zone macrophages (MZM) or CD169+ metallophilic 
macrophages. Together, along with other subcapsular cell types, 
these macrophages orchestrate and modulate the resulting 
humoral immune response. We hypothesized that the function of 
these subcapsular macrophages cannot be recapitulated by DCs 
or B cells, and therefore, the lack of MyD88 signaling in these 
cells could explain the significant effect on the OVA-specific IgG 
response in the Mac-MyD88−/− mice. We do not believe that the 
antigen presentation by macrophages, which could be affected 
by a defect in MyD88 signaling in these cells, because DC func-
tion in the Mac-MyD88−/− mice should be normal, including its 
major antigen presentation function, but still, normal DCs can-
not substitute for the function of macrophages lacking MyD88. 
Therefore, we next investigated the effect of MyD88 deficiency on 
the induction of GCs upon immunization with OVA formulated 
with PorB, CpG, or alum.
FigUre 3 | In vivo MyD88 signaling in macrophages differentially affects the induction of Th2 and Th1 type cytokines upon immunization with 
toll-like receptor ligand-based adjuvants. (a–c) Th2 type (IL-4, IL-5, and IL-13) and (D,e) Th1 type (IL-12 and IFN-γ) cytokines level in individual mouse serum 
of wild-type (WT), Mac-MyD88−/−, B-cell-MyD88−/−, and DC-MyD88−/− mice immunized two times at 2 weeks interval and serum collected 4 h after of the second 
immunization with PBS, ovalbumin (OVA), OVA + PorB, OVA + CpG, or OVA + alum measured by Luminex magnetic bead-based multiplex assay. The results 
shown are representative of one experiment (n = 4 mice); serum was analyzed individually in duplicates. This experiment was repeated twice. Symbol (–) indicates 
that cytokine levels were below detectable level. One-way ANOVA with Tukey’s test were used to calculate statistical differences between experimental groups and 
treatments (ns, not significant P > 0.05, *P < 0.05, **P < 0.01). All comparisons were made to WT mice.
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Splenic GC size and number were determined at various time 
points after immunizations. Seven days after the second immu-
nization yielded the most consistent and replicable production of 
GCs in WT mice and was consequently used to assess GC responses 
for all further experiments. We found a significant decrease in the 
area of GC in the spleens of Mac-MyD88−/− mice when compared 
with WT mice, after immunization with TLR ligand-based adju-
vant PorB or CpG (Figures 4A–C). Interestingly, Mac-MyD88−/− 
mice form equivalent GC areas, as compared to WT mice, when 
immunized with TLR-independent adjuvant alum (similar to 
the antibody responses) or when injected with sheep red blood 
cells as a positive control (Figures 4A,C). This demonstrates that 
the decrease in GC formation when TLR ligand-based adjuvants 
were used was not due to an intrinsic defect in GC formation in 
the Mac-MyD88−/− mice, but rather due to the specific lack of 
signaling through MyD88.
As mentioned, we observed a decrease in OVA-specific IgG in 
DC-MyD88−/− and B-cell-MyD88−/− mice, when immunized with 
TLR ligand-based adjuvants (Figure 1). This is consistent with 
previous studies demonstrating that TLR9 signaling in DCs and B 
cells controls the magnitude of the GC reaction upon immuniza-
tion with vaccine formulated with the TLR9 ligand, CpG (48). 
Therefore, we compared GC formation in Mac-MyD88−/− mice, 
with DC-MyD88−/− and B-cell-MyD88−/− mice. We found a 
similar decrease in GC formation in DC-MyD88−/− mice in 
comparison with Mac-MyD88−/− mice, when immunized with 
OVA formulated with PorB as adjuvant. GC formation was not 
impaired DC-MyD88−/− mice immunized with OVA along with 
FigUre 4 | Formations of germinal centers (gcs) in the spleen are dependent on in vivo MyD88 signaling in macrophages upon immunization with 
toll-like receptor ligand-based adjuvants. (a) GC responses examined by confocal microscopy 7 days after the second immunization, 8 μm thick spleen 
sections were prepared and examined as described “Animals and Methods.” Sections were stained for IgD follicular B cell marker (red), GC B cell marker GL7 
(green), and T cell marker TCR-β (cyan). (B) A spleen section with the GC area measured using the freehand selection tool in ImageJ, here the area of GC (green) is 
encircled in white. (c) Quantitation of GC areas by ImageJ. There were three mice per immunization group, 6 sections per spleen that are at least 40 μm apart and a 
total of 18 sections were examined per group. (D) Percentage of GC cells from spleen was measured by flow cytometry 7 days after the second immunization and 
gating for B220+CD4−CD19+GL7+GC cells. The results shown are representative of at least two experiments with a total of eight mice per immunization group for 
the flow cytometry analysis experiment. One-way ANOVA with Tukey’s test were used (ns, not significant P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001).
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TLR-independent adjuvant alum. We did not observe a decrease 
in GC formation in B-cell MyD88−/− mice immunized with either 
OVA/PorB (Figure 4C), although we did find that these mice did 
not mount an anti-OVA humoral response (Figure 1). This sug-
gests that intact in vivo MyD88 signaling in B cells is not required 
for GC formation, but is required for specific antibody produc-
tion when PorB is used as an adjuvant. This disconnection of GC 
formation vs. antibody production in the B cell MyD88−/− mice 
is unique and suggests that MyD88 in B cells is essential for TLR-
mediated induction plasma cells and antibody production but not 
for GC formation. Further studies are planned to investigate this 
phenomenon.
Ovalbumin formulated with CpG induced large GC areas as 
compared to any other adjuvants in WT mice (Figure 4C) and 
triggered the highest percentage of CD4−B220+CD19+GL7+GC 
B cells (GC B cells) (Figure  4D). GCs were decreased in 
Mac-MyD88−/− immunized with OVA+CpG (Figure  4D). 
However, many of the small GC areas triggered by CpG in 
Mac-MyD88−/− mice were larger than 400  μm2 and therefore 
measurable by ImageJ in contrast to PorB formulation, which 
yielded mainly GC areas smaller than 400 μm2. This may explain 
why there was a residual amount of GC area detected in Mac-
MyD88−/− mice for CpG formulated vaccines (Figure  4C). 
Nevertheless, we found a significant decrease in GC formation 
with TLR ligand-based adjuvant in Mac-MyD88−/− mice in both 
analysis methods, quantification of immunofluorescence, and 
flow cytometry. Mice immunized with OVA alone in contrast 
produced very few GL7+ areas, and PBS-injected mice showed 
none by confocal microscopy. Flow cytometric analysis allowed 
a more precise survey of the entire spleen with an accurate assess-
ment of the presence GC B cells (B220+CD4−CD19+GL7+). This 
presumably accounts for the limitation of missing the formation 
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of GC in immunofluorescence quantification and their detec-
tion in the flow cytometric analysis. The residual GC cells in 
non-immunized mice are likely due to baseline responses to 
other antigens that the mice are exposed to in the animal facility 
and/or background staining of the cells. Notably, there was no 
decrease in GC area and cell numbers with vaccines contain-
ing TLR-independent adjuvants in these Mac-MyD88−/− mice 
(Figure 4D). These findings demonstrate a major role of intact 
MyD88 signaling in macrophages for robust GC formation 
(along with antibody formation, as previously described) when 
TLR ligands are used as adjuvants.
DiscUssiOn
In the present study, we provide detailed insight into the in vivo role 
of TLR signaling through MyD88 in B cells, DCs, or macrophages 
for TLR ligand-based vaccine adjuvant activity. MyD88 is an 
essential adaptor-signaling molecule for all TLRs except TLR3 
and the TRIF/TRAM signaling pathway for TLR4 (49). Complete 
MyD88−/− mice have reported defects in the induction of humoral 
responses using OVA and LPS in Complete Freund’s adjuvant 
(22), live virus infections (50, 51), with inactivated influenza virus 
(51, 52), or with OVA/PorB as we have previously demonstrated 
(39). We found that in  vivo MyD88 signaling, individually, in 
three different APC types (B cells, macrophages, or DCs), was 
essential for the adjuvant activity of PorB and CpG, both TLR 
ligands that signal through MyD88. The most unique finding of 
this study was that mice with a macrophage-specific MyD88 dele-
tion had a decrease in T-cell-dependent antibody responses upon 
immunization with vaccines formulated with TLR ligand-based 
adjuvants PorB or CpG, as compared to immunized WT mice. 
In contrast, TLR-independent adjuvants, alum and MF59, were 
able to induce a robust antibody response in mice with MyD88 
deletion in specific APC types.
Previous studies highlighted the importance of TLR/MyD88 
signaling in B cells and DCs for the induction of antibodies 
in vivo (22, 25). Therefore, it was not as surprising to observe a 
decrease in the humoral response in the DC-MyD88−/− and B-cell-
MyD88−/− mice in our experiments. This was especially evident in 
studies where MyD88 signaling in B cells in vivo was shown to be 
critical for induction of antibody-secreting cells upon vaccination 
(19), important for induction anti-retroviral GC responses (20) 
and required for induction of functional CD4 T cells producing 
IFN-γ to control IgG2c subclass production (21–23). Recent 
studies have shown that TLR-MyD88 signaling in DCs is required 
for induction of antibodies when immunized with vaccine 
containing soluble TLR9 ligands using DC-MyD88−/− mice (27). 
Our observations of a decrease in T-cell-dependent antibody 
responses in DC-MyD88−/− and B-cell MyD88−/− mice with the 
use of different TLR ligand-based adjuvants were consistent with 
these previous published findings. However, the requirement of 
MyD88 signaling in macrophages for in vivo TLR ligand-based 
vaccine adjuvant activity has never been demonstrated or previ-
ously investigated.
An essential immunological process that is required for the pro-
duction of significant amounts of high affinity T-cell-dependent 
antibodies is the generation of GCs. These are transient structures 
that form within secondary lymphoid organs in response to 
antigens (24) and are the main source of memory B cells, as 
well as plasma cells producing high levels of antigen-specific 
antibodies of different subclasses (53). In the current study, we 
have demonstrated that Mac-MyD88−/− mice had a dramatic 
decrease in both GC formation and the percentage of GC B cells 
found after immunization with vaccines containing TLR ligand 
PorB or CpG as adjuvants. The diminished number and reduced 
area of GC cells is the probable reason why Mac-MyD88−/− mice 
had significantly lower antigen-specific antibody levels upon vac-
cination with MyD88-dependent TLR ligand-based adjuvants, as 
compared to WT mice. As a control, we have shown that Mac-
MyD88−/− mice form normal GCs and antigen-specific antibody 
levels when the TLR-independent adjuvant alum was used in the 
vaccine formulation (or when sheep red blood cells are given), 
indicating that these mice are not inherently impaired in GC 
formation.
It is known that upon subcutaneous immunization, the 
content of the vaccine is partly taken up by the resident DCs or 
macrophages at the immunization site, which then traffic to the 
draining lymph nodes and spleen. The vaccine components can 
also journey to the draining lymph nodes via vitreous pressure. 
Within the secondary lymphoid organs, they encounter unique 
sets of macrophages (54) including metallophillic macrophages 
(MM, CD169+), MZM (MARCO+), red pulp macrophages 
(CD206+), and white pulp macrophages (CD68+, tingible body 
macrophages), with a variety of functions depending on their 
locations in vivo (54). MM CD169+ macrophages line the sub-
capsular sinus of the draining lymph nodes and surround the 
follicular B cells in the spleen; they have been shown to be able to 
capture antigens and present these antigens complexes directly to 
B cells and follicular DC (55). Interestingly, various investigators 
have shown that depletion of macrophages in the spleen resulted 
in an inability to form GCs (56, 57), but the role of MyD88 
signaling in the adjuvant-related function of these cells has not 
been examined. In the set of presented studies, we have revealed 
a unique and, here-to-for, unexamined role of macrophage TLR/
MyD88 signaling in TLR ligand-based adjuvant function, which 
cannot be rescued by normal DC or B cell function. This would 
suggest that the MyD88 defect in macrophages might be uniquely 
affecting MM and MZM function and the reason why these mice 
cannot form GCs when TLR ligands are used as vaccine adjuvants.
Previous studies have shown that mice with B cell-specific 
MyD88 deletion have a significant reduction in GC formation 
upon stimulation with endogenous nucleic acid recognized by 
TLR 9 or 7 in a lupus-like autoimmune disease mouse model 
in Lyn−/− mice (58). Interestingly, even though we observed a 
decrease in OVA-specific antibody responses in the sera of OVA/
PorB immunized B-cell-MyD88−/− mice, we found no significant 
decrease in GC area. This suggests that intact MyD88 signaling 
in B cells is not required for GC formation when PorB is used as 
an adjuvant; however, it likely still required for a switch to plasma 
cells to allow for production of OVA-specific IgG. More studies 
are needed to investigate the decrease in antibody responses in 
B-cell-MyD88−/− mice by examining antibody-secreting cells. 
Another study showed that TLR9 signaling in DCs (soluble 
TLR9) and B cells (virus-like particle associated TLR9) controls 
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the magnitude of the GC reaction upon immunization with vac-
cine formulated with the TLR9 ligand, CpG (48). We observed a 
similar decrease in GC formation in DC-MyD88−/− mice upon 
immunization with TLR/MyD88-dependent adjuvants but not 
with TLR-independent adjuvants.
There is evidence that alum adjuvant activity may be partially 
MyD88 dependent (47), and we do see a reduced antibody 
response in the three APC-MyD88−/− mice strains as compared 
to WT mice when immunized with alum-formulated vaccines. 
However, the decrease in the antibody response was minimal 
when compared to the abrogation of antigen-specific antibod-
ies with TLR ligand-based adjuvants in the MyD88 conditional 
KO mice. MF59 adjuvant activity has been shown to be MyD88 
dependent (12); however, in our studies the antibody levels 
induced when MF59 was used as an adjuvant in the MyD88 con-
ditional KO mice were not greatly affected. Therefore, it is most 
likely that MF59 adjuvant activity requires MyD88 signaling in 
non-hematologic cells (i.e., stromal cells), or more than one APC 
at a time. More studies are needed to identify the cell type or set 
of cell types that are responsible for its adjuvant activity.
In general, multiple cytokines have been shown to be involved 
in adjuvant mediated vaccine-induced immune responses 
(59–61). Here, we found that PorB, as a TLR2 ligand vaccine 
adjuvant, induces high serum levels of many cytokines known 
to be involved with efficacious vaccine responses, including pro-
inflammatory cytokines (IL-1β and IL-6), chemokine (IP-10), 
Th2 type cytokines (IL-4, IL-5, and IL-13), and Th1 type cytokines 
(IL-12 and IFN-γ) in WT mice shortly after immunization. The 
selective deletion of MyD88 in macrophages resulted in a profound 
decrease in most of these effector molecules except for IL-6, IL-4, 
and IFN-γ, which remained unchanged. Adjuvants vary greatly 
in the character and intensity of induced responses (42), and this 
is reflected in the heterogeneity of the observed cytokine levels 
with the different types of adjuvant used in our study. Overall, our 
findings demonstrate that the examined adjuvants induced het-
erogeneous responses and that MyD88 signaling in each of these 
APCs affects the overall profile of cytokine induction induced 
by these adjuvanted OVA formulations. However, at this point, 
it is difficult to ascertain whether these alterations in cytokine 
profiles are directly related to the alterations in adjuvant activity 
and further work is necessary to clarify this process, especially 
in regard to B and T effector and memory cell induction and GC 
formation.
In summary, our major findings indicate that MyD88 sign-
aling in APCs, especially in macrophages, is essential for PorB 
(TLR2 ligand) vaccine adjuvant activity. It also appears that the 
same can be said for CpG, a TLR9 ligand vaccine adjuvant, but 
this is not true for TLR ligand-independent adjuvants like alum 
or MF59. These new insights could aid in vaccine development 
by allowing more intelligent and judicious use of these and other 
vaccine adjuvants to target specific cell types and induce specific 
type of responses. Vaccines containing TLR ligand-based adju-
vants can be formulated and administered in a specific way so 
that they target specific APC types in the lymphoid organs and 
engage specific TLR or sets of TLRs in order to enhance types of 
immune responses needed for protection.
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